Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omalizumab add-on therapy for airway inflammation and remodeling in moderate to severe allergic asthma
NL-OMON32348Phase 4Active, not recruiting
- Sponsor
- Novartis
- Start
- May 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in allergic asthma and asthma comparing Xolair add-on with Placebo add-on (2 arms). Primary endpoint: Change in sub-epithelial eosinophils in bronchial biopsies after 78 weeks. Started May 2009; status: active, not recruiting.
02
Drugs
omalizumab
03
Conditions
allergic asthmaasthma
Beyond the preview
Go deeper on NL-OMON32348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON32348.